局限性前列腺癌中度大分割(70 Gy/28次)调强放疗的十年结局
单中心连续854例局限性前列腺癌患者接受70 Gy/28次(2.5 Gy/次)中度大分割调强放疗并每日影像引导,中位随访11.3年。低危、有利中危、不利中危和高危组10年生化无复发生存率分别为88%、78%、71%和42%(P<.0001),10年肿瘤特异性死亡率分别为2%、5%、5%和15%,≥3级泌尿和胃肠毒性10年累积发生率分别为2%和1%。作者认为该方案对所有风险组患者似乎可接受。
要点
- 低危、有利中危、不利中危和高危组10年生化无复发生存率分别为88%、78%、71%和42%(P<.0001)。
- 全组10年总生存率为69%(95%CI 66%-73%),10年前列腺癌特异性死亡率为6.8%(95%CI 5.1%-8.6%)。
- ≥3级泌尿和胃肠毒性10年累积发生率分别为2%和1%。
核心结论
- 作者认为,每日影像引导下的高剂量中度大分割调强放疗治疗局限性前列腺癌显示出良好的10年肿瘤学结局且毒性发生率低。
- 作者认为该分割方案对所有风险组患者似乎可接受。
研究设计与样本
- 单中心连续纳入1998年至2012年间接受中度大分割调强放疗并每日影像引导的854例局限性前列腺癌患者。
- 单一中危因素者归为有利中危,多个中危因素者归为不利中危。
- 采用Kaplan-Meier分析生化无复发生存、临床无复发生存和总生存,采用竞争风险回归分析前列腺癌特异性死亡。
- ≥3级泌尿和胃肠毒性按常见不良事件评价标准4.03版记录并计算累积发生率。
主要发现
- 中位随访11.3年(最长19年)。
- 低危、有利中危、不利中危和高危组10年生化无复发生存率分别为88%、78%、71%和42%(P<.0001)。
- 低危、有利中危、不利中危和高危组10年临床无复发生存率分别为95%、91%、85%和72%(P<.0001)。
- 全组10年 actuarial 总生存率为69%(95%CI 66%-73%),10年前列腺癌特异性死亡率为6.8%(95%CI 5.1%-8.6%)。
- 低危、有利中危、不利中危和高危组10年前列腺癌特异性死亡率分别为2%、5%、5%和15%;≥3级泌尿和胃肠毒性10年累积发生率分别为2%和1%。
关键数值与推荐
- 放疗方案为70 Gy分28次,每次2.5 Gy,采用调强放疗并每日影像引导。
- 低危、有利中危、不利中危和高危组10年生化无复发生存率分别为88%、78%、71%和42%(P<.0001)。
- 全组10年总生存率为69%(95%CI 66%-73%),10年前列腺癌特异性死亡率为6.8%(95%CI 5.1%-8.6%)。
- ≥3级泌尿和胃肠毒性10年累积发生率分别为2%和1%。
临床怎么用
- 作者认为,每日影像引导下的高剂量中度大分割调强放疗用于局限性前列腺癌可获得良好的10年肿瘤学结局且毒性发生率低。
- 作者认为该分割方案对所有风险组患者似乎可接受。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Long-term outcomes with hypofractionated radiation therapy for prostate cancer are limited. We report 10-year outcomes for patients treated with intensity modulated radiation therapy (IMRT) for localized prostate cancer with 70 Gy in 28 fractions at 2.5 Gy per fraction. METHODS AND MATERIALS: The study included 854 consecutive patients with localized prostate cancer treated with moderately hypofractionated IMRT and daily image guidance at a single institution between 1998 and 2012. Patients with a single intermediate risk factor were considered to have favorable intermediate-risk (FIR) disease, and those with multiple intermediate risk factors were considered unfavorable (UIR). Biochemical relapse-free survival, clinical relapse-free survival, and overall survival were analyzed using Kaplan-Meier analysis. Prostate cancer-specific mortality (PCSM) was analyzed using competing risk regression. All grade ≥3 genitourinary (GU) and gastrointestinal (GI) toxicities were recorded using Common Terminology Criteria for Adverse Event version 4.03, and cumulative incidence rates of GU and GI toxicity were calculated. RESULTS: The median follow-up was 11.3 years (maximum, 19 years). For patients with low-risk (LR), FIR, UIR, and high-risk (HR) disease, the 10-year biochemical relapse free survival rates were 88%, 78%, 71%, and 42%, respectively, (P < .0001). The 10-year clinical relapse free survival were 95%, 91%, 85%, and 72% for patients with LR, FIR, UIR, and HR, respectively, (P < .0001). For all patients, the 10-year actuarial overall survival rate was 69% (95% confidence interval, 66%-73%), and the 10-year PCSM was 6.8% (95% confidence interval, 5.1%-8.6%) overall. For patients with LR, FIR, UIR and HR disease, the 10-year PCSM rates were 2%, 5%, 5%, and 15%. Long-term grade ≥3 GU or GI toxicity remained low with 10-year cumulative incidences of 2% and 1%, respectively. CONCLUSIONS: High-dose moderately hypofractionated IMRT with daily image guidance for localized prostate cancer demonstrates favorable 10-year oncologic outcomes with a low incidence of toxicity. This fractionation schedule appears to be acceptable for patients across all risk groups.
引用
- Abu-Gheida I, Reddy CA, Kotecha R, et al. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 30721720. doi:10.1016/j.ijrobp.2019.01.091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。